Breaking News

WuXi PharmaTech Completes Suzhou Biosafety Testing Facility

May 13, 2014

Expands platform of biologics services

WuXi PharmaTech has completed construction of its new biosafety testing facility in Suzhou. The facility has 38,000 sq.-ft. of labs and support areas, and is located next to WuXi's GLP preclinical drug safety facility. Operations will begin this summer, once validations are completed. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for local and multinational customers.
 
"WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "By investing in capabilities that address our customers' needs, we have become a leading biologics solution provider."

Related Compliance:

  • Biopharma Fill Finish Contract Manufacturing Market

    Biopharma Fill Finish Contract Manufacturing Market

    Cindy Liu and William Downey, HighTech Business Decisions||November 9, 2016
    Outsourcing strategies and areas of market opportunities

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research